Viatris Inc

VTRS: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
TZbLOCK|X%?LOCK|H%<k?!

Viatris: Trial Miss Adds More Pressure to Recovery of Core Business to Gain Investor Confidence

Viatris announced that the phase 3 study of MR-139 (pimecrolimus) for blepharitis did not meet its primary endpoints.

Sponsor Center